NanoViricides Inc. (NNVC)

[changes_iv]

About two years ago NanoViricides, Inc. started firming out contracts and non-disclosure agreements with different expert organizations.

WEST HAVEN, Conn.--(BUSINESS WIRE)--Jul 23, 2012 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has retained Australian Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide™, the Company's broad-spectrum anti-influenza drug. Australian Biologics will also facilitate clinical trial site(s) selection and development of the clinical trials agreements.
AT-M Ad

Dr. Jim Ackland, the Manager of Australian Biologics Pty, Ltd, has extensive experience in this field. Prior to becoming managing director of this company, he was Vice-President, West Coast and Asia Pacific operations for the Biologics Consulting Group, the Company's US FDA regulatory affairs consulting group. In the 1990's, he was the Head of Regulatory Affairs, Vaccines, for the CSL Group in Australia. The CSL Group is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.

“We are very pleased to engage Jim and his staff because of their extensive experience in both the regulatory and operational aspects of the clinical trials landscape in Australia,” stated Eugene Seymour, MD, MPH, Chief Executive Officer of the Company.

source: http://www.drugs.com/clinical_trials/nanoviricides-retains-consulting-firm-expedite-first-flucide-human-trials-australia-14091.html

We have a state-of-the-art manufacturing Pilot Plant nearing completion...

We will only make drugs

We do no anti-viral testing on site

That's done by our collaborators

Our place will be absolutely beautiful, high-tech and state of the art for our specific needs in creating the nanoviricides

We anticipate that our facility will be the only anti-viral nanomedicine cGMP production facility in the world (or the US for sure)

I was there and was knocked over

The scientists can't wait to move in!

EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics

NanoViricides, Inc. has assembled a marquee team of experienced personnel to help us with the design, architecture, and engineering of this facility. Mr. Andrew Hahn continues to provide overall stewardship for this project. He was formerly Senior Director of Engineering, Pharmaceutical Facilities, Global Engineering, at the Bristol-Myers-Squibb Company Worldwide Medicines Group (BMS). He has almost 30 years of experience in architecture, design and project management in the creation of new and refurbished facilities at Bristol-Myers Squibb Company. Mr. Phil Mader and his firm, MPH Engineering, LLC (“MPH”), continue to help with the overall project management and design engineering of the laboratory and cGMP pilot production facility. Prior to founding MPH, from 2000 to 2007, Phil Mader served as the Senior Capital Project Manager at Bristol-Myers Squibb Company in Wallingford, CT (“BMS”). He was involved in the design, implementation, and commissioning of various biology and chemistry laboratory projects within budget and in a timely manner. Ms. Kathyann Cowles of ID3A, LLC, serves as the Principal Architect. Ms. Cowles, co-founder of Id3A, has over thirty years of experience as a licensed Architect and Senior Project Manager for diverse and complex design and construction projects in the academic, science, technology, corporate and research sectors.
About two years ago posters here were saying it would be (5) to (7) years before our small company would reach clinical trials. Unless something catastrophic were to happen, we should be in the Clinical Trials within the year (2014-2015).

source: http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Reports%20on%20Construction%20Progress%20of%20its%20New%20Facility%20and%20cGMP%20Pilot%20Production%20Plant.html

Find a list of independent collaborators in last year's video (advance video to 16:05 min)

Some posters here were saying it will be 5, 7, years before our small company reaches clinical trials. We now know it should be within the year (barring a catastrophic event).

You may want to write to those collaborators and see what they have to say about nanoviricides otherwise, as daBoze would say, "...patience grasshopper, patience..."